Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors

In recent years, it has become increasingly evident that cancer cells and the local microenvironment are crucial in the development and progression of tumors. One of the major components of the tumor microenvironment is the extracellular matrix (ECM), which comprises a complex mixture of components, including proteins, glycoproteins, proteoglycans, and polysaccharides. In addition to providing structural and biochemical support to tumor tissue, the ECM undergoes remodeling that alters the biochemical and mechanical properties of the tumor microenvironment and contributes to tumor progression and resistance to therapy. A novel concept has emerged, in which tumor-driven ECM remodeling affects the release of ECM components into peripheral blood, the levels of which are potential diagnostic or prognostic markers for tumors. This review discusses the most recent evidence on ECM remodeling-derived signals that are detectable in the bloodstream, as new early diagnostic and risk prediction tools for the most frequent solid cancers.

[1]  P. Mack,et al.  Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004 , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  C. Colpaert,et al.  A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation , 2007, Histopathology.

[3]  S. Pitson,et al.  The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity , 2018, Front. Oncol..

[4]  E. Fadel,et al.  Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer , 2016, BMC Cancer.

[5]  P. Naredi,et al.  Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer , 2009, British Journal of Cancer.

[6]  Ugo Pastorino,et al.  Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer , 2018, BMC Cancer.

[7]  M. Ayers,et al.  Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers , 2008, British Journal of Cancer.

[8]  A. Bankfalvi,et al.  Matrix metalloproteinase‐7 as a marker of metastasis and predictor of poor survival in bladder cancer , 2010, Cancer science.

[9]  Nikos K. Karamanos,et al.  Matrix modeling and remodeling: A biological interplay regulating tissue homeostasis and diseases. , 2019, Matrix biology : journal of the International Society for Matrix Biology.

[10]  M. Koch,et al.  Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer , 2014, OncoTarget.

[11]  I. Kovalszky,et al.  Validation of Circulating MMP-7 Level as an Independent Prognostic Marker of Poor Survival in Urinary Bladder Cancer , 2011, Pathology & Oncology Research.

[12]  M. Yen,et al.  A case–cohort study for the disease natural history of adenoma–carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy , 2003, British Journal of Cancer.

[13]  P. Naredi,et al.  Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement , 2015, Tumor Biology.

[14]  F. Tanaka,et al.  Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. , 2013, Clinical lung cancer.

[15]  J. Angulo,et al.  El papel de la metaloproteinasa de la matriz MMP-9 y del inhibidor tisular de metaloproteinasa TIMP-2 como marcadores séricos de cáncer vesical , 2013 .

[16]  Jane L Meza,et al.  MUC4 Mucin Potentiates Pancreatic Tumor Cell Proliferation, Survival, and Invasive Properties and Interferes with Its Interaction to Extracellular Matrix Proteins , 2007, Molecular Cancer Research.

[17]  R. Muschel,et al.  A core matrisome gene signature predicts cancer outcome , 2018, British Journal of Cancer.

[18]  V. Weaver,et al.  The extracellular matrix modulates the hallmarks of cancer , 2014, EMBO reports.

[19]  H. Reis,et al.  Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method , 2016, International Urology and Nephrology.

[20]  E. Salido,et al.  Plasma matrix metalloproteinase 9 as an early surrogate biomarker of advanced colorectal neoplasia. , 2016, Gastroenterologia y hepatologia.

[21]  In‐San Kim,et al.  Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer , 2016, Oncotarget.

[22]  Witold Rzyman,et al.  European position statement on lung cancer screening. , 2017, The Lancet. Oncology.

[23]  Chwee Teck Lim,et al.  An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer , 2017, Nature Communications.

[24]  Terry Hyslop,et al.  Clinical Significance of Serum COL6A3 in Pancreatic Ductal Adenocarcinoma , 2013, Journal of Gastrointestinal Surgery.

[25]  Giuseppe Merlino,et al.  Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. , 2015, Seminars in cancer biology.

[26]  T. Zima,et al.  Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression. , 2017, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[27]  M. Karsdal,et al.  Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study. , 2015, Cancer biomarkers : section A of Disease markers.

[28]  R. Sanz-Pamplona,et al.  Discovery and Validation of New Potential Biomarkers for Early Detection of Colon Cancer , 2014, PloS one.

[29]  P. Sinues,et al.  Noninvasive strategies for breast cancer early detection. , 2016, Future oncology.

[30]  M. Karsdal,et al.  High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts , 2018, International journal of cancer.

[31]  A. Schneeweiss,et al.  Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer , 2016, International journal of cancer.

[32]  J. Crowley,et al.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Z. Daniil,et al.  Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9 , 2016, Cancer investigation.

[34]  B. Mroczko,et al.  The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients , 2010, International Journal of Colorectal Disease.

[35]  S. Ménard,et al.  Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress , 2013, PloS one.

[36]  K. Harada,et al.  Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib. , 2014, Urologic oncology.

[37]  J. Liao,et al.  TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis , 2018, PloS one.

[38]  Z. Werb,et al.  The Role of Stroma in Tumor Development. , 2015, Cancer journal.

[39]  C. Haglund,et al.  Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer , 2018, BMC Cancer.

[40]  P. Naredi,et al.  Type IV collagen as a tumour marker for colorectal liver metastases. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[41]  V. Torri,et al.  Soluble stroma‐related biomarkers of pancreatic cancer , 2018, EMBO molecular medicine.

[42]  R. Miceli,et al.  Extracellular matrix proteins as diagnostic markers of breast carcinoma , 2018, Journal of cellular physiology.

[43]  Cynthia A. Reinhart-King,et al.  Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials , 2018, Science Translational Medicine.

[44]  C. Yeo,et al.  Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. , 2011, Surgery.

[45]  Z. Werb,et al.  Remodelling the extracellular matrix in development and disease , 2014, Nature Reviews Molecular Cell Biology.

[46]  G. Vozzi,et al.  ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2D‐DIGE Proteomics , 2018, Proteomics.

[47]  A. Ferruelo,et al.  The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer. , 2013, Actas urologicas espanolas.

[48]  K. Grabowski,et al.  Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers , 2009, Clinical chemistry and laboratory medicine.

[49]  G. Mælandsmo,et al.  Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease , 2018, BMC Cancer.

[50]  T. Pihlajaniemi,et al.  Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers , 2014, British Journal of Cancer.

[51]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[52]  K. Ohba,et al.  Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and Metastasis , 2006, Clinical Cancer Research.

[53]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[54]  S. Ergün,et al.  Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer , 2012, International journal of cancer.

[55]  R. Kalluri,et al.  Tumor stroma derived biomarkers in cancer , 2009, Cancer and Metastasis Reviews.

[56]  Ju-Han Lee,et al.  Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis. , 2011, Journal of gastrointestinal and liver diseases : JGLD.

[57]  R. Holder,et al.  Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test , 2012, British Journal of Cancer.

[58]  Jacob J. Kennedy,et al.  Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. , 2011, Cancer research.

[59]  M. Karsdal,et al.  Tumstatin, a Matrikine Derived from Collagen Type IVα3, is Elevated in Serum from Patients with Non–Small Cell Lung Cancer , 2018, Translational oncology.

[60]  M. Karsdal,et al.  Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer , 2014, Cancer medicine.

[61]  P. Naredi,et al.  Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. , 2015, Cancer biomarkers : section A of Disease markers.

[62]  M. Callari,et al.  Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. , 2015, Seminars in cancer biology.

[63]  M. Karsdal,et al.  Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients , 2016, Scientific Reports.

[64]  E. Wang,et al.  A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer. , 2013, Journal of proteomics.

[65]  M. Papotti,et al.  Progressive Increase of Matrix Metalloprotease-9 and Interleukin-8 Serum Levels during Carcinogenic Process in Human Colorectal Tract , 2012, PloS one.

[66]  F. Liu,et al.  Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics , 2015, Oncotarget.

[67]  S. Carr,et al.  Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver , 2014, BMC Cancer.

[68]  Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls , 2013, BMC Cancer.

[69]  J. Karlsson,et al.  The extracellular matrix – the under‐recognized element in lung disease? , 2016, The Journal of pathology.

[70]  Hans H Schild,et al.  Breast cancer risk assessment: a non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes , 2016, Amino Acids.

[71]  J. Raufman,et al.  The Role of Matrix Metalloproteinases in Colorectal Cancer , 2014, Cancers.

[72]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.